An inactivated Covid-19 vaccine candidate developed by Chinese scientists produced a robust immune response and mild side effects in early stage testing, according to a new study.
Get the latest insights and analysis from our Global Impact newsletter on the big stories originating in China. The trial involved 320 healthy adults, aged 18 to 59. They were given four different kinds of injections – either a placebo, or a low, medium or high dose of the vaccine candidate.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Explainer: How do vaccines and immune systems work, and why could a coronavirus vaccine fail?
Source: TODAYonline - 🏆 1. / 99 Read more »
Russia produces first batch of coronavirus vaccineMOSCOW (AFP) - Russia said on Saturday (Aug 15) that it has produced the first batch of its coronavirus vaccine, after President Vladimir Putin announced it had been first in the world to approve a vaccine.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »
Coronavirus: Chinese regulator says vaccines must have 50 per cent efficacy, give 6 months’ immunityCovid-19 vaccines must have an efficacy rate of 50 per cent and provide at least six months’ immunity if they are to be approved for use in China, the country’s drug regulator has announced.According to a draft document released by the Chinese Centre for Drug Evaluation (CCDE), 50 per cent is the minimum
Source: YahooSG - 🏆 3. / 71 Read more »
COVID-19 vaccine developer CureVac shares surge in US debutShares of German biotechnology firm CureVac BV nearly tripled in their Nasdaq debut on Friday, marking the first stock market debut of a company ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Mexico needs 200 million COVID-19 vaccine doses; shots could start in AprilMexico will need up to 200 million coronavirus vaccine doses, according to a senior government official, and inoculation of its 120 million ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Coronavirus vaccine developer CureVac raises US$213.3 million in US IPOCureVac BV said on Friday it raised US$213.3 million in its initial public offering in New York, setting the stage for the first stock market ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »